UPLOAD Filing
Aspire Biopharma Holdings, Inc.
Date: May 20, 2025 · CIK: 0001847345 · Accession: 0000000000-25-005403
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287240
Letter
Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed May 13, 2025 File No. 333-287240 Dear Kraig T. Higginson:
May 20, 2025
Kraig T. Higginson Chief Executive Officer and Chairman Aspire Biopharma Holdings, Inc. 194 Candelaro Drive, #233 Humacao, PR 00791
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Arthur Marcus, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 20, 2025 Kraig T. Higginson Chief Executive Officer and Chairman Aspire Biopharma Holdings, Inc. 194 Candelaro Drive, #233 Humacao, PR 00791 Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 Filed May 13, 2025 File No. 333-287240 Dear Kraig T. Higginson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Arthur Marcus, Esq. </TEXT> </DOCUMENT>